Crossref Cited-by Linking logo

Collect. Czech. Chem. Commun. 1992, 57, 661-672
https://doi.org/10.1135/cccc19920661

Metabolism of 1-(S)-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine (HPMPC) in Human Embryonic Lung Cells

Tomas Cihlar, Ivan Votruba, Květoslava Horská, Radek Liboska, Ivan Rosenberg and Antonín Holý

Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, 166 10 Prague 6

Crossref Cited-by Linking

  • Coremans Georges, Snoeck Robert: Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions. Expert Opinion on Pharmacotherapy 2009, 10, 1343. <https://doi.org/10.1517/14656560902960154>
  • Votruba Ivan, Hájek Miroslav, Kaiserová Helena, Tloušťová Eva, Krečmerová Marcela, Holý Antonín: Biochemical Evaluation of a New Potential Antiviral Drug HPMP-5-Azacytosine. Antiviral Research 2008, 78, A66. <https://doi.org/10.1016/j.antiviral.2008.01.146>
  • Horská Květoslava, Votruba Ivan, Holý Antonín: Interaction of Phosphates of the Acyclic Nucleoside Phosphonates with Nucleoside Diphosphate Kinase from Yeast and Bovine Liver. Collect. Czech. Chem. Commun. 2006, 71, 35. <https://doi.org/10.1135/cccc20060035>
  • Wakisaka Naohiro, Yoshizaki Tomokazu, Raab‐Traub Nancy, Pagano Joseph S.: Ribonucleotide reductase inhibitors enhance cidofovir‐induced apoptosis in EBV‐positive nasopharyngeal carcinoma xenografts. Intl Journal of Cancer 2005, 116, 640. <https://doi.org/10.1002/ijc.21096>
  • Afouna Mohsen I, Fincher Timothy K, Zaghloul Abdel-Azim A, Reddy Indra K: Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice. International Journal of Pharmaceutics 2003, 253, 159. <https://doi.org/10.1016/S0378-5173(02)00705-6>
  • De Clercq Erik: Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin Microbiol Rev 2003, 16, 569. <https://doi.org/10.1128/CMR.16.4.569-596.2003>
  • Wolf Daniel L., Rodríguez Carlos A., Mucci Massimiliano, Ingrosso Antonella, Duncan Barbara A., Nickens Dana J.: Pharmacokinetics and Renal Effects of Cidofovir with a Reduced Dose of Probenecid in HIV‐Infected Patients with Cytomegalovirus Retinitis. The Journal of Clinical Pharma 2003, 43, 43. <https://doi.org/10.1177/0091270002239705>
  • De Clercq Erik: Cidofovir in the treatment of poxvirus infections. Antiviral Research 2002, 55, 1. <https://doi.org/10.1016/S0166-3542(02)00008-6>
  • Holý Antonín, Otová Berta, Buděšínský Miloš, Emerson David, Wiles Marc E.: O-Phosphonatomethylcholine, Its Analogues, Alkyl Esters, and Their Biological Activity. J. Med. Chem. 2001, 44, 4462. <https://doi.org/10.1021/jm010974h>
  • Cihlar Tomas, Ho Edmund S., Lin Deborah C., Mulato Andrew S.: HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS. Nucleosides, Nucleotides and Nucleic Acids 2001, 20, 641. <https://doi.org/10.1081/NCN-100002341>
  • De Clercq Erik: Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections. Clin Microbiol Rev 2001, 14, 382. <https://doi.org/10.1128/CMR.14.2.382-397.2001>
  • Otmar Miroslav, Masojídková Milena, Votruba Ivan, Holý Antonín: An Alternative Synthesis of HPMPC and HPMPA Diphosphoryl Derivatives. Collect. Czech. Chem. Commun. 2001, 66, 500. <https://doi.org/10.1135/cccc20010500>
  • Birkuš Gabriel, Votruba Ivan, Otmar Miroslav, Holý Antonín: Interactions of 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) Diphosphate with DNA Polymerases α, δ and ε*. Collect. Czech. Chem. Commun. 2001, 66, 1698. <https://doi.org/10.1135/cccc20011698>
  • Krejc̆ová Romana, Horská Kvĕtoslava, Votruba Ivan, Holý Antonı́n: Interaction of guanine phosphonomethoxyalkyl derivatives with GMP kinase isoenzymes. Biochemical Pharmacology 2000, 60, 1907. <https://doi.org/10.1016/S0006-2952(00)00512-8>
  • Krejčová Romana, Horská Květoslava, Votruba Ivan, Holý Antonín: Phosphorylation of Purine (Phosphonomethoxy)alkyl Derivatives by Mitochondrial AMP Kinase (AK2 Type) from L1210 Cells. Collect. Czech. Chem. Commun. 2000, 65, 1653. <https://doi.org/10.1135/cccc20001653>
  • HO EDMUND S., LIN DEBORAH C., MENDEL DIRK B., CIHLAR TOMAS: Cytotoxicity of Antiviral Nucleotides Adefovir and Cidofovir Is Induced by the Expression of Human Renal Organic Anion Transporter 1. JASN 2000, 11, 383. <https://doi.org/10.1681/ASN.V113383>
  • Leung Daniel T., Sacks Stephen L.: Current Recommendations for the Treatment of Genital Herpes. Drugs 2000, 60, 1329. <https://doi.org/10.2165/00003495-200060060-00007>
  • Compton Mindy L, Toole John J, Paborsky Lisa R: 9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-Phosphonylmethoxyethyl)guanine (PMEG). Biochemical Pharmacology 1999, 58, 709. <https://doi.org/10.1016/S0006-2952(99)00138-0>
  • Afouna Mohsen I., Mehta Samir C., Ghanem Abdel‐Halim, Higuchi William I., Kern Earl R., Declercq Erik, El‐Shattawy Hamed H.: Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV‐1 infection in hairless mice. Journal of Pharmaceutical Sciences 1999, 88, 530. <https://doi.org/10.1021/js980406y>
  • Eisenberg Eugene J, Lynch Geoffrey R, Bidgood Alison M, Krishnamurty Krish, Cundy Kenneth C: Isolation and identification of a metabolite of cidofovir from rat kidney. Journal of Pharmaceutical and Biomedical Analysis 1998, 16, 1349. <https://doi.org/10.1016/S0731-7085(97)00162-3>
  • Kendle Julie B, Fan-Havard Patty: Cidofovir in the Treatment of Cytomegaloviral Disease. Ann Pharmacother 1998, 32, 1181. <https://doi.org/10.1345/aph.17312>
  • Safrin Sharon, Cherrington Julie, Jaffe Howard S.: Clinical uses of cidofovir. Rev Med Virol 1997, 7, 145. <https://doi.org/10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0>
  • Safrin Sharon, Cherrington Julie, Jaffe Howard S.: Clinical uses of cidofovir. Rev. Med. Virol. 1997, 7, 145. <https://doi.org/10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0>
  • Mendel D B, Cihlar T, Moon K, Chen M S: Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob Agents Chemother 1997, 41, 641. <https://doi.org/10.1128/AAC.41.3.641>
  • De Clercq E: In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997, 10, 674. <https://doi.org/10.1128/CMR.10.4.674>
  • Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E: HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections. Antivir Chem Chemother 1997, 8, 1. <https://doi.org/10.1177/095632029700800101>
  • Hitchcock M. J. M., Jaffe H. S., Martin J. C., Stagg R. J.: Cidofovir, a New Agent with Potent Anti-Herpesvirus Activity. Antivir Chem Chemother 1996, 7, 115. <https://doi.org/10.1177/095632029600700301>
  • Cundy Kenneth C., Lynch Geoffrey, Shaw Jeng-Pyng, Hitchcock Michael J. M., Lee William A.: Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Current Eye Research 1996, 15, 569. <https://doi.org/10.3109/02713689609000768>
  • Aspe Elena, Guy Richard H., Lee William A., Kennedy James A., Visor Gary C., Ennis Richard D.: Optimization ofin VitroFlux Through Hairless Mouse Skin of Cidofovir, a Potent Nucleotide Analog. Journal of Pharmaceutical Sciences 1995, 84, 750. <https://doi.org/10.1002/jps.2600840617>
  • Mendel D B, Barkhimer D B, Chen M S: Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 1995, 39, 2120. <https://doi.org/10.1128/AAC.39.9.2120>
  • Neyts Johan, De Clercq Erik: Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. Biochemical Pharmacology 1994, 47, 39. <https://doi.org/10.1016/0006-2952(94)90435-9>
  • Snoeck R., Andrei G., De Clercq E.: Chemotherapy of varicella zoster virus infections. International Journal of Antimicrobial Agents 1994, 4, 211. <https://doi.org/10.1016/0924-8579(94)90011-6>
  • Clercq Erik De: Antiviral Activity Spectrum and Target of Action of Different Classes of Nucleoside Analogues. Nucleosides and Nucleotides 1994, 13, 1271. <https://doi.org/10.1080/15257779408012151>
  • Bischofberger N, Hitchcock M J, Chen M S, Barkhimer D B, Cundy K C, Kent K M, Lacy S A, Lee W A, Li Z H, Mendel D B: 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994, 38, 2387. <https://doi.org/10.1128/AAC.38.10.2387>
  • De Clercq E.: Therapeutic potential of HPMPC as an antiviral drug. Reviews in Medical Virology 1993, 3, 85. <https://doi.org/10.1002/rmv.1980030205>
  • Neyts J., De Clercq E.: Strategies for the treatment and prevention of cytomegalovirus infections. International Journal of Antimicrobial Agents 1993, 3, 187. <https://doi.org/10.1016/0924-8579(93)90012-T>